1
|
Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated Approach to Early Detection of Cardiovascular Toxicity Induced by a Ghrelin Receptor Agonist. Int J Toxicol 2015; 34:151-61. [DOI: 10.1177/1091581815573029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Cardiovascular (CV) safety concerns are among the leading causes of compound attrition in drug development. This work describes a strategy of applying novel end points to a 7-day rodent study to increase the opportunity to detect and characterize CV injury observed in a longer term (ie, 28 days) study. Using a ghrelin receptor agonist (GSK894281), a compound that produces myocardial degeneration/necrosis in rats after 28 days at doses of 0.3, 1, 10, or 60 mg/kg/d, we dosed rats across a range of similar doses (0, 0.3, 60, or 150 mg/kg/d) for 7 days to determine whether CV toxicity could be detected in a shorter study. End points included light and electron microscopies of the heart; heart weight; serum concentrations of fatty acid-binding protein 3 (FABP3), cardiac troponin I (cTnI), cardiac troponin T (cTnT), and N-terminal proatrial natriuretic peptide (NT-proANP); and a targeted transcriptional assessment of heart tissue. Histologic evaluation revealed a minimal increase in the incidence and/or severity of cardiac necrosis in animals administered 150 mg/kg/d. Ultrastructurally, mitochondrial membrane whorls and mitochondrial degeneration were observed in rats given 60 or 150 mg/kg/d. The FABP3 was elevated in rats given 150 mg/kg/d. Cardiac transcriptomics revealed evidence of mitochondrial dysfunction coincident with histologic lesions in the heart, and along with the ultrastructural results support a mechanism of mitochondrial injury. There were no changes in cTnI, cTnT, NT-proANP, or heart weight. In summary, enhancing a study design with novel end points provides a more integrated evaluation in short-term repeat dose studies, potentially leading to earlier nonclinical detection of structural CV toxicity.
Collapse
Affiliation(s)
- Alan H. Stokes
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - J. Greg Falls
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - Lawrence Yoon
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - Neal Cariello
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - Brenda Faiola
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
- Present address: Becton, Dickinson and Company, Corporate Preclinical Development and Toxicology, Durham, NC, USA
| | - Heidi M. Colton
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - Holly L. Jordan
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| | - Brian R. Berridge
- GlaxoSmithKline Research and Development, Safety Assessment, Research Triangle Park, NC, USA
| |
Collapse
|
2
|
Leivers M, Miller JF, Chan SA, Lauchli R, Liehr S, Mo W, Ton T, Turner EM, Youngman M, Falls JG, Long S, Mathis A, Walker J. Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism. J Med Chem 2013; 57:1964-75. [DOI: 10.1021/jm401337x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Martin Leivers
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - John F. Miller
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Stephanie A. Chan
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Ryan Lauchli
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Sebastian Liehr
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
- Santen Inc., 2100 Powell Street,
Suite 1600, Emeryville, California 94608, United States
| | - Wenyan Mo
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
- ChemPartner Co., 998 Halei Road, Shanghai 201203, China
| | - Tony Ton
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
- Principia Biopharma, Inc., 400
East Jamie Court, Suite 302, South San Francisco, California 94080, United States
| | - Elizabeth M. Turner
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Michael Youngman
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
- Lieber Institute For Brain Development, 855 North Wolfe Street, Suite 300, Baltimore, Maryland 21205, United States
| | - J. Greg Falls
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Susan Long
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| | - Amanda Mathis
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
- Nonclinical
and Clinical Pharmacology, Salix Pharmaceuticals, Inc., 8510 Colonnade
Center Drive, Raleigh, North
Carolina 27615, United States
| | - Jill Walker
- GlaxoSmithKline Research & Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, United States
| |
Collapse
|
3
|
Kwanyuen P, Witherspoon SM, Creech DR, Colton HM, Falls JG, Cariello NF. Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys. Int J Toxicol 2006; 25:41-7. [PMID: 16510356 DOI: 10.1080/10915810500488395] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Multiple methods currently exist for the assessment of peroxisome proliferation, including gene expression, enzyme activity, immunolabeling coupled with image analysis, and electron microscopy. This study describes a novel flow cytometric method to efficiently quantify peroxisome proliferation in cells from frozen livers. Frozen livers from cynomolgus monkeys treated with ciprofibrate at doses of 0, 3, 30, 150, and 400 mg/kg/day for 15 days were mechanically disaggregated using an automated dispersion method. The resulting cell suspensions were labeled using an allophycocyanin (APC)-conjugated antibody directed against peroxisomal membrane protein 70 (PMP70). Statistically significant increases in mean fluorescence intensity were observed from animals dosed at 30, 150, and 400 mg/kg/day compared to control. Parallel comparisons using electron microscopy and immunofluorescence microscopy suggest that flow cytometry may be an alternative to electron microscopy in determinations of peroxisome proliferation. Flow cytometric analysis of freshly isolated hepatocytes and frozen liver from rats treated with fenofibrate at 200 mg/kg/day for 10 days showed the flow cytometric method could detect peroxisome proliferation in both species. The research described here demonstrates the feasibility of applying flow cytometry for the detection of peroxisome proliferation.
Collapse
Affiliation(s)
- Puntipa Kwanyuen
- GlaxoSmithKline, Inc., Safety Assessment, Investigative Toxicology and Pathology, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | |
Collapse
|
4
|
Cariello NF, Romach EH, Colton HM, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol Sci 2005; 88:250-64. [PMID: 16081524 DOI: 10.1093/toxsci/kfi273] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists that have been in clinical use for many decades for treatment of dyslipidemia. When mice and rats are given PPARalpha agonists, these drugs cause hepatic peroxisome proliferation, hypertrophy, hyperplasia, and eventually hepatocarcinogenesis. Importantly, primates are relatively refractory to these effects; however, the mechanisms for the species differences are not clearly understood. Cynomolgus monkeys were exposed to ciprofibrate at various dose levels for either 4 or 15 days, and the liver transcriptional profiles were examined using Affymetrix human GeneChips. Strong upregulation of many genes relating to fatty acid metabolism and mitochondrial oxidative phosphorylation was observed; this reflects the known pharmacology and activity of the fibrates. In addition, (1) many genes related to ribosome and proteasome biosynthesis were upregulated, (2) a large number of genes downregulated were in the complement and coagulation cascades, (3) a number of key regulatory genes, including members of the JUN, MYC, and NFkappaB families were downregulated, which appears to be in contrast to the rodent, where JUN and MYC are reported to upregulated after PPARalpha agonist treatment, (4) no transcriptional signal for DNA damage or oxidative stress was observed, and (5) transcriptional signals consistent with an anti-proliferative and a pro-apoptotic effect were seen. We also compared the primate data to literature reports of hepatic transcriptional profiling in PPARalpha-treated rodents, which showed that the magnitude of induction in beta-oxidation pathways was substantially greater in the rodent than the primate.
Collapse
Affiliation(s)
- Neal F Cariello
- GlaxoSmithKline Inc., Safety Assessment, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Colton HM, Falls JG, Ni H, Kwanyuen P, Creech D, McNeil E, Casey WM, Hamilton G, Cariello NF. Visualization and Quantitation of Peroxisomes Using Fluorescent Nanocrystals: Treatment of Rats and Monkeys with Fibrates and Detection in the Liver. Toxicol Sci 2004; 80:183-92. [PMID: 15084755 DOI: 10.1093/toxsci/kfh144] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Peroxisome proliferation in the liver is a well-documented response that occurs in some species upon treatment with hypolipidemic drugs, such as fibrates. Typically, liver peroxisome proliferation has been estimated by direct counting via electron microscopy, as well as by gene expression, enzyme activity, and immunolabeling. We have developed a novel method for the immunofluorescent labeling of peroxisomes, using an antibody to the 70-kDa peroxisomal membrane protein (PMP70) coupled with fluorescent nanocrystals, Quantum Dots. This method is applicable to standard formalin-fixed, paraffin-embedded tissues. Using this technique, a dose-dependent increase in PMP70 labeling was evident in formalin-fixed liver sections from fenofibrate-treated rats. In formalin-fixed liver sections from cynomolgus monkeys given ciprofibrate, quantitative image analysis showed a statistically significant increase in PMP70 labeling compared to control; the increase in hepatic PMP70 protein levels was corroborated by immunoblotting using total liver protein. An increase in hepatic peroxisome number in ciprofibrate-treated monkeys was confirmed by electron microscopy. An advantage of the Quantum Dot/PMP70 method is that a single common protocol can be used to label peroxisomes from several different species, and many of the common problems that arise with immunolabeling, such as fading and low signal strength, are eliminated.
Collapse
Affiliation(s)
- H M Colton
- GlaxoSmithKline, Inc., Safety Assessment, Investigative Toxicology and Pathology, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Cherrington NJ, Falls JG, Rose RL, Clements KM, Philpot RM, Levi PE, Hodgson E. Molecular cloning, sequence, and expression of mouse flavin-containing monooxygenases 1 and 5 (FMO1 and FMO5). J Biochem Mol Toxicol 2000; 12:205-12. [PMID: 9580872 DOI: 10.1002/(sici)1099-0461(1998)12:4<205::aid-jbt2>3.0.co;2-p] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Full-length cDNA clones encoding FMO1 and FMO5 have been isolated from a library constructed with mRNA from the liver of a female CD-1 mouse. The derived sequence of FMO1 contains 2310 bases: 1596 in the coding region, 301 in the 5'-flanking region, and 413 in the 3'-flanking region. The sequence for FMO5 consists of 3168 bases; 1599 in the coding region, 812 in the 5'-flanking region, and 757 in the 3'-flanking region. The sequence of FMO1 encodes a protein of 532 amino acids with a predicted molecular weight of 59.9 kDa and shows 83.3% identity to human FMO1 and 83-94% identity to other FMO1 homologs. FMO5 encodes a protein of 533 amino acids with a predicted molecular weight of 60.0 kDa and 84.1% identity to human FMO5 and 83-84% identity to other FMO5 orthologs. Two GxGxxG putative pyrophosphate binding domains exist beginning at positions 9 and 191 for FMO1, and 10 and 192 for FMO5. Mouse FMO1 and FMO5 were expressed in E. coli and show similar mobility to the native proteins as determined by SDS-PAGE. The expressed FMO1 protein showed activity toward methimazole, and FMO5 was active toward noctylamine. In addition, FMO1 was shown to metabolize radiolabeled phorate, whereas FMO5 showed no activity toward phorate.
Collapse
Affiliation(s)
- N J Cherrington
- Department of Toxicology, North Carolina State Universitiy, Raleigh 27695, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Wilson VS, McLachlan JB, Falls JG, LeBlanc GA. Alteration in sexually dimorphic testosterone biotransformation profiles as a biomarker of chemically induced androgen disruption in mice. Environ Health Perspect 1999; 107:377-84. [PMID: 10210693 PMCID: PMC1566419 DOI: 10.1289/ehp.99107377] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Assessment of the impact of environmental chemicals on androgen homeostasis in rodent models is confounded by high intraindividual and interindividual variability in circulating testosterone levels. Our goal was to evaluate changes in testosterone biotransformation processes as a measure of androgen homeostasis and as a biomarker of exposure to androgen-disrupting chemicals. Sex-specific differences in hepatic testosterone biotransformation enzyme activities were identified in CD-1 mice. Gonadectomy followed by replacement of individual steroid hormones identified specific sex differences in biotransformation profiles that were due to the inductive or suppressive effects of testosterone. Notably, significant androgen-dependent differences in testosterone 6[alpha]- and 15[alpha]-hydroxylase activities were demonstrated, and the ratio of 6[alpha]- and 15[alpha]-hydroxylase activities proved to be an excellent indicator of the androgen status within the animal. The male or "masculinized" testosterone 6[alpha]/15[alpha]-hydroxylase ratio was significantly less than the female or "feminized" ratio. Male mice were exposed to both an antiandrogen, vinclozolin, and to a compound that modulates serum androgen levels, indole-3-carbinol, to test the utility of this ratio as a biomarker of androgen disruption. Treatment with the antiandrogen vinclozolin significantly increased the 6[alpha]/15[alpha]-hydroxylase ratio. Indole-3-carbinol treatment resulted in a dose-dependent, but highly variable, decrease in serum testosterone levels. The 6[alpha]/15[alpha]-hydroxylase ratio increased as serum testosterone levels decreased in these animals. However, the increase in the ratio was much less variable and more sensitive than serum testosterone levels. These investigations demonstrate that the 6[alpha]/15[alpha]-hydroxylase ratio is a powerful measure of androgen modulation and a sensitive indicator of exposure to androgen-disrupting chemicals in CD-1 mice.
Collapse
Affiliation(s)
- V S Wilson
- Department of Toxicology, North Carolina State University, Raleigh, NC 27695, USA
| | | | | | | |
Collapse
|
8
|
Abstract
Genomic imprinting refers to an epigenetic marking of genes that results in monoallelic expression. This parent-of-origin dependent phenomenon is a notable exception to the laws of Mendelian genetics. Imprinted genes are intricately involved in fetal and behavioral development. Consequently, abnormal expression of these genes results in numerous human genetic disorders including carcinogenesis. This paper reviews genomic imprinting and its role in human disease. Additional information about imprinted genes can be found on the Genomic Imprinting Website at http://www.geneimprint.com.
Collapse
Affiliation(s)
- J G Falls
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina27710, USA
| | | | | | | |
Collapse
|
9
|
Abstract
Polymorphisms have been identified in proto-oncogenes and tumor suppressor genes that predispose people to cancer. Recent evidence indicates that genomic imprinting, an epigenetic form of gene regulation that results in uniparental gene expression, can also function as a cancer predisposing event. Thus, cancer susceptibility is increased by both Mendelian inherited genetic and non-Mendelian inherited epigenetic events. Consequently, chemical and physical agents cannot only induce cancer through the formation of genetic mutations but also through epigenetic changes that result in the inappropriate expression of imprinted proto-oncogenes and tumor suppressor genes. The role of genomic imprinting in carcinogenesis and cancer susceptibility is examined in this review.
Collapse
Affiliation(s)
- D J Pulford
- Department of Safety of Medicines, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
| | | | | | | |
Collapse
|
10
|
Abstract
We have previously shown that inactivation of mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) is a common early event in both human liver and breast carcinogenesis. The M6p/Igf2r is imprinted in mice while expression is biallelic in most humans. In this investigation the M6p/Igf2r gene is shown to also be imprinted in the liver of Fischer 344, Lewis and Brown Norway rats. In addition, we have identified mutations in the expressed allele of the M6p/Igf2r in 40% of diethylnitrosamine-initiated rat liver tumors. These results provide further evidence that the M6P/IGF2R functions as a liver tumor suppressor gene. They also suggest that mice and rats would be more sensitive than humans to those hepatocarcinogens in which the M6p/Igf2r is mechanistically involved in transformation since one rather than two alleles would need to be inactivated.
Collapse
Affiliation(s)
- J J Mills
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | |
Collapse
|
11
|
Falls JG, Cherrington NJ, Clements KM, Philpot RM, Levi PE, Rose RL, Hodgson E. Molecular cloning, sequencing, and expression in Escherichia coli of mouse flavin-containing monooxygenase 3 (FMO3): comparison with the human isoform. Arch Biochem Biophys 1997; 347:9-18. [PMID: 9344459 DOI: 10.1006/abbi.1997.0322] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The sequence of mouse flavin-containing monooxygenase 3 (FMO3) was obtained from several clones isolated from a mouse liver cDNA library. The nucleotide sequence of mouse FMO3 was 2020 bases in length containing 37 bases in the 5' flanking region, 1602 in the coding region, and 381 in the 3' flanking region. The derived protein sequence consisted of 534 amino acids including the putative flavin adenine dinucleotide and NADP+ pyrophosphate binding sites (characteristic of mammalian FMOs) starting at positions 9 and 191, respectively. The mouse FMO3 protein sequence was 79 and 82% identical to the human and rabbit FMO3 sequences, respectively. Mouse FMO3 was expressed in Escherichia coli and compared to E. coli expressed human FMO3. The FMO3 proteins migrated with the same mobility ( approximately 58 kDa) as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. The expressed FMO3 enzymes (mouse and human forms) were sensitive to heat and reacted in a similar manner toward metal ions and detergent. Catalytic activities of mouse and human FMO3 were high toward the substrate methimazole; however, in the presence of trimethylamine and thioacetamide, FMO-dependent methimazole oxidation by both enzymes was reduced by greater than 85%. Other substrates which inhibited methimazole oxidation were thiourea and thiobenzamide and to a lesser degree N,N-dimethylaniline. When probed with mouse FMO3 cDNA, FMO3 transcripts were detected in hepatic mRNA samples from female mice, but not in samples from males. FMO3 was detected in mRNA samples from male and female mouse lung, but FMO3 message was not detected in mouse kidney sample from either gender. Results of immunoblotting confirmed the tissue- and gender-dependent expression of mouse FMO3.
Collapse
Affiliation(s)
- J G Falls
- Department of Toxicology, North Carolina State University, Raleigh, North Carolina 27695, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Based on enzyme activity, protein levels, and mRNA levels, we have previously demonstrated the female-predominant, female-specific, and gender-independent expression in mouse liver of FMO forms 1, 3, and 5, respectively. This study investigated the roles of testosterone, 17 beta-estradiol, and progesterone in the regulation of hepatic FMOs. FMO expression was examined in gonadectomized CD-1 mice, normal CD-1 mice receiving hormonal implants, and gonadectomized mice receiving various hormonal treatments. Following castration of males, hepatic FMO activity levels were significantly increased and serum testosterone levels significantly decreased; however, administration of physiological levels of testosterone to castrated animals returned FMO activity and testosterone concentrations to control levels. When sexually intact and ovariectomized female mice were treated with testosterone, their hepatic FMO activity levels were reduced to those of their male counterparts, concomitant with high serum testosterone levels. In males, castration dramatically increased FMO3 and FMO1 expression, and testosterone replacement to castrated males resulted in ablation of FMO3 expression. In addition, testosterone administration to females (sexually intact and gonadectomized animals) reduced FMO1 expression and obviated FMO3 expression. In females, ovariectomy alone slightly reduced FMO activity, indicative of a possible stimulatory role of female sex steroids; however, female FMO isozyme expression was relatively unchanged, and hormone replacement therapy to ovariectomized females had no discernible effect. In males and females, FMO5 levels were unaffected by gonadectomy or hormone administration, thus indicating a sex hormone-independent mechanism of regulation for this isoform. Interestingly, FMO1 protein levels were increased in sexually intact males following treatment with 17 beta-estradiol; however, only a slight increase in FMO3 protein level was observed. No positive hormone effectors of female FMO expression were identified.
Collapse
Affiliation(s)
- J G Falls
- Department of Toxicology, North Carolina State University, Raleigh 27695, USA
| | | | | | | | | |
Collapse
|
13
|
Falls JG, Blake BL, Cao Y, Levi PE, Hodgson E. Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice. J Biochem Toxicol 1995; 10:171-7. [PMID: 7473608 DOI: 10.1002/jbt.2570100308] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Hepatic flavin-containing monooxygenase (FMO) activity of microsomes from adult CD-1, Swiss-Webster, C57BL/6, and DBA/2 mice was found to be significantly higher in females than in males. Based on protein and mRNA levels in CD-1 mice, FMO forms responsible for the gender difference in FMO activity were FMO1 and FMO3. FMO1 expression was two to three times higher in female mice compared with males; FMO3, however, which was expressed at levels equivalent to FMO1 in female mice, was not detected in males. The expression of FMO5 was approximately equal in both sexes. FMO2 and FMO4 transcripts were not evident in hepatic mRNA from mice. Protein and mRNA levels appear to be coregulated with regard to gender-selective or gender-specific expression of FMO1 or FMO3, respectively. FMO5, which demonstrates no gender-selective expression in mice, may be regulated by different mechanisms. Examination of protein levels among Swiss-Webster, C57BL/6, and DBA/2 strains revealed a gender-dependent expression of FMO isozymes identical to the CD-1 strain.
Collapse
Affiliation(s)
- J G Falls
- Department of Toxicology, North Carolina State University, Raleigh 27695, USA
| | | | | | | | | |
Collapse
|
14
|
Egaas E, Falls JG, Svendsen NO, Ramstad H, Skaare JU, Dauterman WC. Strain- and sex-specific differences in the glutathione S-transferase class pi in the mouse examined by gradient elution of the glutathione-affinity matrix and reverse-phase high performance liquid chromatography. Biochim Biophys Acta 1995; 1243:256-64. [PMID: 7873571 DOI: 10.1016/0304-4165(94)00138-n] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A gradient elution with glutathione (GSH) from a GSH-Sepharose 6B affinity column separated the hepatic mouse glutathione S-transferases (GST) to the alpha-, mu- and pi-classes. The GST-dependent conjugation of atrazine and glutathione was catalyzed by a pi-class GST. The pi- and mu-classes were both identified by their respective specific substrates, and after reverse-phase HPLC, by N-terminal analysis of 19-35 of the amino acids. The alpha-class GST was associated with a high selenium-independent GSH peroxidase activity and the purified protein had a N-blocked terminal. Strain related differences in the pi-class GST of the CD-1, C57BL/6, DBA/2 and Swiss-Webster males were observed by PhastGel electrophoresis of the GSH affinity chromatograph separated fractions, reverse phase HPLC and by N-terminal amino acid sequence analysis.
Collapse
Affiliation(s)
- E Egaas
- Norwegian Plant Protection Institute, Fellesbygget, As Norway
| | | | | | | | | | | |
Collapse
|
15
|
Egaas E, Falls JG, Dauterman WC. A study of gender, strain and age differences in mouse liver glutathione-S-transferase. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995; 110:35-40. [PMID: 7749601 DOI: 10.1016/0742-8413(94)00079-p] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The hepatic cytosolic glutathione S-transferase (GST) activity in four strains of the mouse and one strain of the rat was studied with the substrates 1-chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene (DCNB), ethachrynic acid (ETHA), cumene hydroperoxide (CU) and atrazine as the in vitro substrates. In the mouse, significant gender, strain and age-related differences in the GST activity towards CDNB and atrazine were found between adolescent and sexually mature males and females of the CD-1, C57BL/6, DBA/2 and Swiss-Webster strains, and the differences were larger with atrazine as the substrate. With DCNB and CU a similar tendency was observed, however not significant for all strains. The GST activity towards ETHA was also gender and strain specific, but revealed no age-related differences. The herbicide atrazine seems to be a useful substrate in the study of strain and age-related differences in the mouse GST class Pi.
Collapse
Affiliation(s)
- E Egaas
- Norwegian Plant Protection Institute, As
| | | | | |
Collapse
|
16
|
Egaas E, Skaare JU, Svendsen NO, Sandvik M, Falls JG, Dauterman WC, Collier TK, Netland J. A comparative study of effects of atrazine on xenobiotic metabolizing enzymes in fish and insect, and of the in vitro phase II atrazine metabolism in some fish, insects, mammals and one plant species. Comp Biochem Physiol C Comp Pharmacol Toxicol 1993; 106:141-9. [PMID: 7903609 DOI: 10.1016/0742-8413(93)90265-m] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
1. Atrazine (3 daily i.p. doses of 0.20 mg/kg or 10 ppb in the water for 14 days) did not change the xenobiotic metabolizing enzyme activities (XME) towards the substrates aldrin epoxidase (AE), NADPH-cytochrome c reductase (NCCR), 7-ethoxyresorufin O-deethylase (EROD), 1-chloro-2,4-dinitro-benzene (CDNB) and 1,2-dichloro-4-nitrobenzene (DCNB) in trout liver (Oncorhynchus mykiss) compared to the controls. 2. Various treatment regimens of atrazine in a semisynthetic diet changed the XME activities towards AE, NCCR, CDNB and DCNB in the cabbage moth (Mamestra brassica L.) soft tissues and midgut compared to the controls. 3. A life-long cabbage diet induced the XME activity towards CDNB in the cabbage moth soft tissues and midgut, whereas no differences in the activities towards AE, NCCR and DCNB were observed compared to controls on a semi-synthetic diet. 4. The cabbage moth GSTs bound poorly to a glutathione (GSH)-linked epoxy-activated Sepharose 6-B; however, based on the CDNB activity recovered by a GSH elution, there were no differences in the molecular weights of the partly purified subunits (27, 26 and 25 kDa) or the pIs (5.4, 4.8, and 4.1) of the molecules in the soft tissues or midguts from respectively atrazine treated and control cabbage moth.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- E Egaas
- Norwegian Plant Protection Institute, As, Norway
| | | | | | | | | | | | | | | |
Collapse
|